MTOR and renal cell carcinoma: The efficiency of Sapanisertib, a third generation ATP competitive inhibitor of mTOR, has been demonstrated in vitro and in vivo in breast carcinoma [56], bladder carcinoma [57], and renal cell carcinoma [58].